Viking Therapeutics Inc. is diving more deeply into developing obesity treatments and investors like an accelerated timetable the company has proposed. On June 25, Viking shares (NASDAQ:VKTX) catapulted 28.3% upward to close at $64.68 each.
Injectable glucagon-like peptide 1 receptor (GLP-1R) agonists have shown efficacy in weight management and glycemic control. Semaglutide is available as an oral formulation, but it requires specific timing and conditions. Carmot Therapeutics Inc. has presented data for its oral GLP-1R agonist CT-996 from preclinical studies in obesity; the drug is currently in early clinical development.
The same mechanism of action deployed by Eli Lilly and Co.’s obesity drug Mounjaro (tirzepatide) helped lure Roche Holding AG to the buyout of Carmot Therapeutics Inc., as the pharma giant agreed to pay $2.7 billion up front for the privately held outfit, promising another $400 million if milestones are met.
Carmot Therapeutics Inc. has divulged benzimidazoyl compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of metabolic diseases.
Carmot Therapeutics Inc. has raised $160 million in series D financing to support a trio of early to midstage clinical programs focused on treating diabetes and obesity with peptide-based small-molecule incretin receptor modulators.
